Figure 2. Hemodynamic measurements of the effects of PH and sac/val treatment on (A) RV maximum pressure, (B) stroke volume, (C) heart rate, (D) dp/dt max, (E) dp/dt min, (F) PA elastance (Ea), (G) RV elastance (Ees), and (H) ratio of RV to PA elastance $\left(\frac{\mathbf{\text{Ees}}}{\mathbf{\text{Ea}}}\right)$.

Sac/val treatment significantly lowered RV maximum pressure (P_max), decreased the load‐dependent measure of contractility $(\text{dp}/\text{dt}\text{max})$, increased the load‐dependent measure of relaxation $(\text{dp}/\text{dt}\text{min})$ and decreased PA elastance (Ea) in addition to preventing RV‐PA uncoupling. Horizontal line (―) and cross (✕) representing median and mean of distributions, respectively. Kruskal–Wallis tests with pairwise Wilcoxon rank sum post hoc testing. *P<0.05 compared with control, ^† P<0.05 compared with PH. $\frac{\text{dp}}{\text{dt}}$max and min indicates maximum and minimum of the time derivative of pressure; BPM, beats per minute; PA, pulmonary artery; PH, pulmonary hypertension; RV, right ventricle; RVU, relative volume units; and Sac/Val, sacubitril/valsartan.